50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#121

Vancomycin

AntimicrobialVancocinFirvanq

A glycopeptide antibiotic that has been a cornerstone treatment for serious Gram-positive infections including MRSA for decades, working by inhibiting bacterial cell wall synthesis.

Share:

Overview

Vancomycin is a glycopeptide antibiotic originally isolated from the soil organism Amycolatopsis orientalis (formerly Nocardia orientalis) in 1953 by Edmund Kornfeld at Eli Lilly. It was introduced into clinical use in 1958 and has since become one of the most important antibiotics in medicine, particularly for treating serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive organisms.

The mechanism of action involves binding to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the cell wall precursor peptide (lipid II). This binding physically blocks the transpeptidase and transglycosylase enzymes that cross-link peptidoglycan strands, preventing proper cell wall synthesis. The large molecular size of vancomycin means it acts on the external face of the cell membrane without needing to enter the bacterial cell, which is fundamentally different from beta-lactam antibiotics.

Vancomycin has been called the "antibiotic of last resort," though this designation is increasingly shared with newer agents. It remains the empiric treatment of choice for suspected MRSA infections in hospitalized patients. It is also the first-line oral treatment for Clostridioides difficile infection (CDI), where it acts locally in the gut without significant systemic absorption. The development of vancomycin-resistant Enterococci (VRE) and vancomycin-intermediate/resistant S. aureus (VISA/VRSA) represents one of the most concerning developments in antimicrobial resistance.

Modern use of vancomycin emphasizes therapeutic drug monitoring (TDM). Current guidelines recommend targeting an area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC) of 400-600 for serious MRSA infections, a shift from the older trough-based monitoring approach. This AUC-guided dosing improves efficacy while reducing nephrotoxicity.

Research Uses & Applications

  • Treatment of serious MRSA infections including bacteremia, endocarditis, and osteomyelitis
  • First-line oral treatment for Clostridioides difficile infection (CDI)
  • Empiric coverage for suspected Gram-positive infections in hospitalized patients
  • Surgical prophylaxis in patients with beta-lactam allergies or in institutions with high MRSA rates
  • Treatment of central nervous system infections (meningitis) caused by resistant organisms via intrathecal administration
  • Peritoneal dialysis-related peritonitis treatment via intraperitoneal administration

Key Research Findings

  • Updated IDSA/ASHP/SIDP guidelines (2020) recommend AUC-guided vancomycin dosing (target AUC/MIC 400-600) over trough-based monitoring for MRSA infections.
  • The ORBIT trial and meta-analyses showed oral vancomycin is effective for C. difficile infection, with fidaxomicin being preferred for recurrent episodes.
  • Emergence of vancomycin resistance: VRE first reported in 1986, VISA in 1997, and VRSA (MIC ≥ 16 mg/L) first reported in 2002.
  • Pharmacokinetic studies showed continuous infusion vancomycin may achieve target concentrations more reliably with potentially less nephrotoxicity than intermittent dosing.
  • Research confirmed vancomycin-associated nephrotoxicity is largely mediated by oxidative stress in proximal tubular cells and is dose- and duration-dependent.

Risks & Side Effects

  • Nephrotoxicity is the most significant adverse effect, particularly with prolonged use, high doses, or concurrent nephrotoxic agents.
  • Red man syndrome (histamine-mediated flushing and hypotension) can occur with rapid infusion; mitigated by slower infusion rates.
  • Ototoxicity (hearing loss) is reported but rare at standard therapeutic concentrations.
  • Vancomycin-resistant organisms represent a major public health threat.
  • Neutropenia may occur with prolonged courses exceeding 7-14 days.

Administration

IV: typically 15-20 mg/kg every 8-12 hours for serious infections, with loading doses of 25-30 mg/kg for critically ill patients. AUC-guided dosing is now preferred. Infused over at least 1 hour to prevent red man syndrome. Oral: 125 mg four times daily for 10 days for C. difficile infection (acts locally in the gut). Intrathecal: 5-20 mg daily for CNS infections. Therapeutic drug monitoring is essential for IV therapy.

Legal Status

FDA-approved prescription antibiotic. Available in IV and oral formulations. Generic vancomycin widely available. Brand names include Vancocin (oral) and Firvanq (oral solution). Listed on the WHO Model List of Essential Medicines. Classified as a critically important antimicrobial by the WHO.

Frequently Asked Questions

What is Vancomycin?

A glycopeptide antibiotic that has been a cornerstone treatment for serious Gram-positive infections including MRSA for decades, working by inhibiting bacterial cell wall synthesis.

What are the main uses of Vancomycin?

The primary research applications of Vancomycin include: Treatment of serious MRSA infections including bacteremia, endocarditis, and osteomyelitis; First-line oral treatment for Clostridioides difficile infection (CDI); Empiric coverage for suspected Gram-positive infections in hospitalized patients; Surgical prophylaxis in patients with beta-lactam allergies or in institutions with high MRSA rates; Treatment of central nervous system infections (meningitis) caused by resistant organisms via intrathecal administration; Peritoneal dialysis-related peritonitis treatment via intraperitoneal administration.

What are the risks and side effects of Vancomycin?

Documented risks and side effects include: Nephrotoxicity is the most significant adverse effect, particularly with prolonged use, high doses, or concurrent nephrotoxic agents.; Red man syndrome (histamine-mediated flushing and hypotension) can occur with rapid infusion; mitigated by slower infusion rates.; Ototoxicity (hearing loss) is reported but rare at standard therapeutic concentrations.; Vancomycin-resistant organisms represent a major public health threat.; Neutropenia may occur with prolonged courses exceeding 7-14 days.. Always consult a healthcare professional before considering any peptide.

Is Vancomycin legal?

FDA-approved prescription antibiotic. Available in IV and oral formulations. Generic vancomycin widely available. Brand names include Vancocin (oral) and Firvanq (oral solution). Listed on the WHO Model List of Essential Medicines. Classified as a critically important antimicrobial by the WHO.

How is Vancomycin administered?

IV: typically 15-20 mg/kg every 8-12 hours for serious infections, with loading doses of 25-30 mg/kg for critically ill patients. AUC-guided dosing is now preferred. Infused over at least 1 hour to prevent red man syndrome. Oral: 125 mg four times daily for 10 days for C. difficile infection (acts locally in the gut). Intrathecal: 5-20 mg daily for CNS infections. Therapeutic drug monitoring is essential for IV therapy.

Related Peptides

#116

Nisin

Antimicrobial

#117

Polymyxin B

Antimicrobial

#118

Bacitracin

Antimicrobial

#119

Gramicidin

Antimicrobial

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #120 Daptomycin#122 Colistin →